(Q38167380)

30 August 2017

title

Varicella zoster: an update on current treatment options and future perspectives (English)

1 reference

30 August 2017

Sharon R Kim

1

1 reference

30 August 2017

Farhan Khan

2

1 reference

30 August 2017

Marigdalia K Ramirez-Fort

3

1 reference

30 August 2017

Christopher Downing

4

1 reference

30 August 2017

Stephen K Tyring

5

1 reference

30 August 2017

language of work or name

English

0 references

publication date

30 November 2013

1 reference

Expert Opinion on Pharmacotherapy

30 August 2017

published in

1 reference

30 August 2017

volume

15

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

61-71

1 reference

Contagiousness of varicella in vaccinated cases: a household contact study

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

THE EPIDEMIOLOGY OF VARICELLA-ZOSTER VIRUS INFECTIONS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Near elimination of varicella deaths in the US after implementation of the vaccination program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Pain and its persistence in herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

How should we measure pain in herpes zoster?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Family History as a Risk Factor for Herpes Zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Crystal-induced acute renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Adverse pregnancy outcome in women exposed to acyclovir during pregnancy: a population-based observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Preclinical development of antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Foscarnet and crystals in glomerular capillary lumens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Foscarnet and pancytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Acyclovir treatment of varicella in otherwise healthy children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Varicella-zoster virus pneumonia in adults: report of 14 cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Prophylaxis of intravenous immunoglobulin and acyclovir in perinatal varicella

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Herpes zoster guideline of the German Dermatology Society (DDG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Clinical correlates of prolonged pain in Japanese patients with acute herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Famciclovir for the Treatment of Acute Herpes Zoster: Effects on Acute Disease and Postherpetic Neuralgia: A Randomized, Double-Blind, Placebo-Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Acyclovir Halts Progression of Herpes Zoster in Immunocompromised Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Double-blind study comparing 2 dosages of valacyclovir hydrochloride for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Recommendations for the Management of Herpes Zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Prevent rather than treat postherpetic neuralgia by prescribing gabapentin earlier in patients with herpes zoster: comment on "incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute he

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Reduction of postherpetic neuralgia in herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Analgesic therapy in postherpetic neuralgia: a quantitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Gabapentin for the Treatment of Postherpetic Neuralgia: A Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Amitriptyline, but not lorazepam, relieves postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Desipramine relieves postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Treatment of postherpetic neuralgia: a review of therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

"The end of innocence" revisited: resistance of herpesviruses to antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Development of Resistance to Acyclovir during Chronic Infection with the Oka Vaccine Strain of Varicella‐Zoster Virus, in an Immunosuppressed Child

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.860443

10.1517/14656566.2014.860443

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference